Web Alert: Medistem to Host Conference Call Today at 12 Noon ET to Discuss Newly Opened Stem Cell Clinic, Other News; Company CEO to Review Recent Milestones and Mission to Develop and Commercialize Stem Cell Therapies.SCOTTSDALE, Ariz. -- Medistem Laboratories, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :MDSM MDSM Mass Digital Storage Management ) (FWB (Fixed Wireless Broadband) See fixed wireless. :S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell Adult stem cells are undifferentiated cells found throughout the body that divide to replenish dying cells and regenerate damaged tissues. Also known as somatic (from Greek Σωματικรณς, of the body sources, will host a live conference call, with a simultaneous webcast, today at 12 noon ET to discuss recent achievements and events. Medistem Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Neil Riordan, Ph.D., will review such milestones as the opening of the Company's first international affiliate stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. bank and patient treatment clinic. The stem cell facility is operated by Medistem's Costa Rican-based affiliate, the Institute for Cellular Medicine (ICM ICM Intercom ICM Integrated Crop Management ICM International Congress of Mathematicians ICM Information Classification and Management ICM Intelligent Contact Management (Cisco) ICM International Creative Management ). During the conference call, Mr. Riordan will provide an overview of the Company's mission to develop, deliver and commercialize advanced medical therapies based on non-controversial adult stem cells. He will also address investor questions. To participate, please register online as explained below. The entire webcast will last approximately 30 minutes.
What: Conference Call with Medistem Laboratories
When: Today, August 14, 2006, at 12 noon Eastern
How: To participate, callers within the United States may
dial (888) 428-4479. When prompted, please tell the
operator that you would like to connect to the
Medistem conference call. International callers can
dial (612) 234-9960.
Cost: The conference call is free of charge.
Webcast: An online audio simulcast of the call will also be
accessible at
http://www.trilogy-capital.com/tcp/medistem/conference.html.
About Medistem Laboratories, Inc. Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young . The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. For more information on Medistem please visit http://www.trilogy-capital.com/tcp/medistem/. Medistem common stock is traded on the Frankfurt, Germany stock exchange under the symbol S2U. Cautionary Statement This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. Certain statements in this release may be "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs administrative costs, n.pl the overhead expenses incurred in the operation of a dental benefits program, excluding costs of dental services provided. . These factors are discussed in greater detail in the company's Registration Statement on Form SB-2 and its quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion